99 related articles for article (PubMed ID: 7805235)
1. Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects.
Ménard J; Boger RS; Moyse DM; Guyene TT; Glassman HN; Kleinert HD
Circulation; 1995 Jan; 91(2):330-8. PubMed ID: 7805235
[TBL] [Abstract][Full Text] [Related]
2. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
[TBL] [Abstract][Full Text] [Related]
3. Renal vascular responses to renin inhibition with zankiren in men.
Fisher ND; Hollenberg N
Clin Pharmacol Ther; 1995 Mar; 57(3):342-8. PubMed ID: 7697952
[TBL] [Abstract][Full Text] [Related]
4. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects.
Lachurié ML; Azizi M; Guyene TT; Alhenc-Gelas F; Ménard J
Circulation; 1995 Jun; 91(12):2933-42. PubMed ID: 7796503
[TBL] [Abstract][Full Text] [Related]
7. Effect of the renin response during renin inhibition: oral Ro 42-5892 in normal humans.
Camenzind E; Nussberger J; Juillerat L; Munafo A; Fischli W; Coassolo P; van Brummelen P; Kleinbloesem CH; Waeber B; Brunner HR
J Cardiovasc Pharmacol; 1991 Sep; 18(3):299-307. PubMed ID: 1720828
[TBL] [Abstract][Full Text] [Related]
8. Effects of SC-56525, a potent, orally active renin inhibitor, in salt-depleted and renal hypertensive dogs.
McMahon EG; Yang PC; Babler MA; Bittner SE; Suleymanov OD; Cain-Janicki KJ; Bedell LJ; Hanson GJ; Cook CS
Hypertension; 1995 Jul; 26(1):95-100. PubMed ID: 7607739
[TBL] [Abstract][Full Text] [Related]
9. Acute effects of a pseudo-tetrapeptide as renin inhibitor on blood pressure and renin-angiotensin system of sodium-repleted and sodium-depleted hypertensive patients.
Denolle T; Luo P; Guyene TT; Cazaubon C; Sissmann J; Corvol P; Ménard J
Arzneimittelforschung; 1993 Feb; 43(2A):255-9. PubMed ID: 8498973
[TBL] [Abstract][Full Text] [Related]
10. A dose-response study of HOE 498, a new non-sulphydryl converting enzyme inhibitor, on blood pressure, pulse rate and the renin-angiotensin-aldosterone system in normal man.
Manhem PJ; Ball SG; Morton JJ; Murray GD; Leckie BJ; Fraser R; Robertson JI
Br J Clin Pharmacol; 1985 Jul; 20(1):27-35. PubMed ID: 2992562
[TBL] [Abstract][Full Text] [Related]
11. The effects of different types and doses of oestrogen replacement therapy on clinic and ambulatory blood pressure and the renin-angiotensin system in normotensive postmenopausal women.
Harvey PJ; Wing LM; Savage J; Molloy D
J Hypertens; 1999 Mar; 17(3):405-11. PubMed ID: 10100079
[TBL] [Abstract][Full Text] [Related]
12. Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081.
Noël B; Del Re G; Capone P; Brunner HR; Nussberger J
J Cardiovasc Pharmacol; 1996 Aug; 28(2):252-8. PubMed ID: 8856481
[TBL] [Abstract][Full Text] [Related]
13. Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans.
Azizi M; Bissery A; Lamarre-Cliche M; Ménard J
Hypertension; 2004 Apr; 43(4):785-90. PubMed ID: 15023936
[TBL] [Abstract][Full Text] [Related]
14. Failure of angiotensin II to suppress plasma renin activity in normotensive subjects with a positive family history of hypertension.
Herlitz H; Palmgren E; Widgren B; Aurell M
Clin Sci (Lond); 2005 Sep; 109(3):311-7. PubMed ID: 15901242
[TBL] [Abstract][Full Text] [Related]
15. Effects of renin inhibitor A-72517 on hemodynamics and cardiac function in sodium-depleted dogs.
Wessale JL; Kleinert HD; Calzadilla SV; Kovar PJ; Rosenberg SH
Am J Hypertens; 1993 Jun; 6(6 Pt 1):514-21. PubMed ID: 8343235
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans.
Azizi M; Bissery A; Peyrard S; Guyene TT; Ozoux ML; Floch A; Ménard J
Clin Pharmacol Ther; 2006 Jan; 79(1):49-61. PubMed ID: 16413241
[TBL] [Abstract][Full Text] [Related]
17. Responses to low dose intravenous perindoprilat infusion in salt deplete/salt replete normotensive volunteers.
MacFadyen RJ; Lees KR; Reid JL
Br J Clin Pharmacol; 1994 Oct; 38(4):329-34. PubMed ID: 7833222
[TBL] [Abstract][Full Text] [Related]
18. Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition.
Kiowski W; Linder L; Kleinbloesem C; van Brummelen P; Bühler FR
Circulation; 1992 Jan; 85(1):1-8. PubMed ID: 1728438
[TBL] [Abstract][Full Text] [Related]
19. Hemodynamic and biochemical consequences of renin inhibition by infusion of CGP 38560A in normal volunteers.
Nussberger J; Delabays A; De Gasparo M; Cumin F; Waeber B; Brunner HR; Ménard J
Hypertension; 1989 Jun; 13(6 Pt 2):948-53. PubMed ID: 2661435
[TBL] [Abstract][Full Text] [Related]
20. Renin inhibitors, angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system.
Schalekamp MA; Derkx FH; van den Meiracker AH
J Hypertens Suppl; 1992 Dec; 10(7):S157-64. PubMed ID: 1291650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
